Journal of Shandong University (Health Sciences) ›› 2021, Vol. 59 ›› Issue (9): 110-116.doi: 10.6040/j.issn.1671-7554.0.2021.0939

Previous Articles     Next Articles

Research progress and clinical characteristics of clinical rapidly progressing prostate cancer

SHI Benkang, CHEN Shouzhen, QU Sifeng, WANG Yong, LIU Lei   

  1. Department of Urology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Published:2021-10-15

RichHTML

9

PDF (PC)

195

Abstract: Prostate cancer is one of the most common malignant tumors in men. Some prostate cancer patients experience rapid disease progression, with recurrence, metastasis and drug resistance in a short period of time, leading to a poor prognosis. Accurately identifying rapidly progressing prostate cancer and taking corresponding treatments can provide survival benefits. This review summarizes the common types of rapidly progressing prostate cancer and their clinical, pathological and molecular characteristics.

Key words: Rapidly progressing prostate cancer, Neuroendocrine, Intraductal carcinoma of the prostate, Gene mutation

CLC Number: 

  • R737.25
[1] Merriel SWD, May MT, Martin RM. Predicting prostate cancer progression: protocol for a retrospective cohort study to identify prognostic factors for prostate cancer outcomes using routine primary care data [J]. BMJ Open, 2018, 8(1): e019409. doi: 10.1136/bmjopen-2017-019409.
[2] Dong L, Zieren R, Xue W, et al. Metastatic prostate cancer remains incurable, why? [J]. Asian J Urol, 2019, 6(1): 26-41.
[3] Semenas J, Allegrucci C, Boorjian SA, et al. Overcoming drug resistance and treating advanced prostate cancer [J]. Curr Drug Targets, 2012, 13(10): 1308-1323.
[4] Ecke TH, Schlechte HH, Schiemenz K, et al. TP53 gene mutations in prostate cancer progression [J]. Anticancer Res, 2010, 30(5): 1579-1586.
[5] Lozano R, Castro E, Aragón IM, et al. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer [J]. Br J Cancer, 2021, 124(3): 552-563.
[6] Beltran H, Demichelis F. Therapy considerations in neuroendocrine prostate cancer: what next? [J] Endocr Relat Cancer, 2021, 28(8): T67-T78.
[7] Alumkal JJ, Sun D, Lu E, et al. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance [J]. Proc Natl Acad Sci U S A, 2020, 117(22): 12315-12323.
[8] Porter LH, Bakshi A, Pook D, et al. Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer [J]. J Pathol, 2021, 254(2): 121-134.
[9] Zhang Z, Zhou C, Li X, et al. Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation [J]. Cancer Cell, 2020, 37(4): 584-598.e11.
[10] Zhang Y, Jin Z, Zhou H, et al. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin [J]. Cancer Med, 2016, 5(6): 1251-1258.
[11] Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer [J]. Nat Rev Cancer, 2015, 15(12): 701-711.
[12] Wang HT, Yao YH, Li BG, et al. Neuroendocrine Prostate Cancer(NEPC)progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis [J]. J Clin Oncol, 2014, 32(30): 3383-3390.
[13] Zaffuto E, Pompe R, Zanaty M, et al. Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis [J]. Clin Genitourin Cancer, 2017, 15(5): e793-e800.
[14] Vlachostergios PJ, Puca L, Beltran H, et al. Emerging variants of castration-resistant prostate cancer [J]. Curr Oncol Rep, 2017, 19(5): 32. doi: 10.1007/s11912-017-0593-6.
[15] Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study [J]. J Clin Oncol, 2018, 36(24): 2492-2503.
[16] Abida W, Cyrta J, Heller G, et al. Genomic correlates of clinical outcome in advanced prostate cancer [J]. Proc Natl Acad Sci U S A, 2019, 116(23): 11428-11436.
[17] Bluemn EG, Coleman IM, Lucas JM, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling [J]. Cancer Cell, 2017, 32(4): 474-489.e6.
[18] Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation [J]. Am J Surg Pathol, 2014, 38(6): 756-767.
[19] Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer [J]. Nat Med, 2016, 22(3): 298-305.
[20] Zhou Z, Flesken-Nikitin A, Corney DC, et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer [J]. Cancer Res, 2006, 66(16): 7889-7898.
[21] Ku SY, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance [J]. Science, 2017, 355(6320): 78-83.
[22] Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets [J]. Cancer discovery, 2011, 1(6): 487-495.
[23] Lee JK, Phillips JW, Smith BA, et al. N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells [J]. Cancer Cell, 2016, 29(4): 536-547.
[24] Wang Y, Wang Y, Ci X, et al. Molecular events in neuroendocrine prostate cancer development [J]. Nat Rev Urol, 2021. doi: 10.1038/s41585-021-00490-0.
[25] Tagawa ST. Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle [J]. J Clin Oncol, 2014, 32(30): 3360-3364.
[26] Tritschler S, Erdelkamp R, Stief C, et al. [Neuroendocrine prostate cancer] [J]. Urologe A, 2017, 56(11): 1475-1484.
[27] Amato RJ, Logothetis CJ, Hallinan R, et al. Chemotherapy for small cell carcinoma of prostatic origin [J]. J Urol, 1992, 147(3 Pt 2): 935-937.
[28] Papandreou CN, Daliani DD, Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate [J]. J Clin Oncol, 2002, 20(14): 3072-3080.
[29] Clarke CL, Graham JD. Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes [J]. PLoS One, 2012, 7(4): e35859. doi: 10.1371/journal.pone.0035859.
[30] Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer [J]. Clin Cancer Res, 2013, 19(13): 3621-3630.
[31] Fléchon A, Pouessel D, Ferlay C, et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer(mCRPC)with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group(GETUG)P01 trial [J]. Ann Oncol, 2011, 22(11): 2476-2481.
[32] Culine S, Demery MEl, Lamy PJ, et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers [J]. J Urol, 2007, 178(3 Pt 1): 844-848.
[33] Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial [J]. Lancet Oncol, 2019, 20(10): 1432-1443.
[34] Szentirmai E, Giannico GA. Intraductal carcinoma of the prostate [J]. Pathologica, 2020, 112(1): 17-24.
[35] Kimura K, Tsuzuki T, Kato M, et al. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens [J]. Prostate, 2014, 74(6): 680-687.
[36] Dinerman BF, Khani F, Golan R, et al. Population-based study of the incidence and survival for intraductal carcinoma of the prostate [J]. Urol Oncol, 2017, 35(12): 673.
[37] de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer [J]. N Engl J Med, 2020, 382(22): 2091-2102.
[38] Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer [J]. J Clin Oncol, 2013, 31(14): 1748-1757.
[39] Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer [J]. N Engl J Med, 2015, 373(18): 1697-1708.
[40] Abida W, Bryce AH, Vogelzang NJ, et al. 793PD-Preliminary results from TRITON2: a phase II study of rucaparib in patients(pts)with metastatic castration-resistant prostate cancer(mCRPC)associated with homologous recombination repair(HRR)gene alterations [J]. Annals of Oncology, 2018, 29(S8): viii272.
[41] Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations(TOPARP-B): a multicentre, open-label, randomised, phase 2 trial [J]. Lancet Oncol, 2020, 21(1): 162-174.
[42] Mota JM, Barnett E, Nauseef JT, et al. Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations [J]. JCO Precis Oncol, 2020, 4: 355-366. doi: 10.1200/po.19.00346.
[43] Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer [J]. N Engl J Med, 2016, 375(5): 443-453.
[44] Antonarakis ES, Shaukat F, Velho PI, et al. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations [J]. Eur Urol, 2019, 75(3): 378-382.
[45] Hause RJ, Pritchard CC, Shendure J, et al. Classification and characterization of microsatellite instability across 18 cancer types [J]. Nat Med, 2016, 22(11): 1342-1350.
[46] Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade [J]. Science, 2017, 357(6349): 409-413.
[47] Robinson D, Allen EMV, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer[J]. Cell, 2015, 161(5): 1215-1228.
[48] Rodrigues DN, Rescigno P, Liu D, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer [J]. J Clin Invest, 2018, 128(10): 4441-4453.
[49] Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making [J]. JCO Precis Oncol, 2017, 2017: PO.17.00029. doi: 10.1200/PO.17.00029.
[50] Velho PI, Silberstein JL, Markowski MC, et al. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer [J]. Prostate, 2018, 78(5): 401-407.
[51] Abida W, Cheng ML, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade [J]. JAMA Oncol, 2019, 5(4): 471-478.
[52] Graff JN, Alumkal JJ, Drake CG, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer [J]. Oncotarget, 2016, 7(33): 52810-52817.
[53] Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer [J]. Nature, 2012, 487(7406): 239-243.
[54] Gan L, Chen S, Wang Y, et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer [J]. Cancer Res, 2009, 69(21): 8386-8394.
[55] Sharma A, Yeow WS, Ertel A, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression [J]. J Clin Investi, 2010, 120(12): 4478-4492.
[56] Chen WS, Aggarwal R, Zhang L, et al. Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer [J]. Eur Urol, 2019, 76(5): 562-571.
[57] Gerhardt J, Montani M, Wild P, et al. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer [J]. Am J Pathol, 2012, 180(12): 848-861.
[58] Li J, Xu C, Lee HJ, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations [J]. Nature, 2020, 580(7801): 93-99.
[59] Bernard D, Pourtier-Manzanedo A, Gil J. Myc confers androgen-independent prostate cancer cell growth [J]. J Clin Invest, 2003, 112(11): 1724-1731.
[60] Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk [J]. N Engl J Med, 2012, 366(2): 141-149.
[61] Wu YM, Cieslik M, Lonigro RJ, et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer [J]. Cell, 2018, 173(7): 1770-1782.e14.
[62] Rescigno P, Gurel B, Pereira R, et al. Characterizing CDK12-mutated prostate cancers [J]. Clin Cancer Res, 2021, 27(2): 566-574.
[1] PAN Pengfei, XU Lisheng, JI Kunqian, WANG Dexiang, LI Yu. Mitochondrial myopathy beginning with respiratory failure: one case and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(2): 54-59.
[2] SUN Yu, CHEN Na, MA Aihua. A case of congenital disorder of glycosylation caused by SLC35A2 gene mutation [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 113-116.
[3] HUANG Xiuli, LIU Bingju, SUN Lifeng. Activated phosphoinositide 3-kinase δ syndrome caused by a mutation in PIK3CD gene: a case report and literature review [J]. Journal of Shandong University (Health Sciences), 2021, 59(3): 107-112.
[4] WANG Zhengyang, XIA Yan, SHI Kaixuan, TAO Kun, WANG Xiaojie. Effects of Trametinib on PAX8 expression in ovarian cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(10): 23-29.
[5] HU Sicui, SUN Qing, WANG Yibing, SUN Lili, SUI Yanxi, LI Tang. Analysis of CLCNKB gene mutation in two families with Bartter syndrome [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 64-70.
[6] LIU Na, LIU Qiji, MOU Kai, CHENG Cuiyun. A case of syndromic neurodevelopmental disorder caused by heterozygous mutation in EBF3 [J]. Journal of Shandong University (Health Sciences), 2020, 58(4): 105-109.
[7] XIA Dandan, WANG Huiyu, XU Junying, LIU Chaoying, WANG Runjie. Small intestinal neuroendocrine tumors: report of 2 cases and literature review [J]. Journal of Shandong University (Health Sciences), 2020, 58(1): 87-90.
[8] FENG Alei, DONG Qing, PANG Jiaohui, YIN Jiani, LI Qiang, HAN Junqing, YANG Zhe. Exploring molecular characteristics of esophageal squamous cell carcinoma based on next-generation sequencing [J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 80-85.
[9] DING Tingting, ZOU Dong, LIU Haochen. An analysis of the mutation of MSX1 gene in a non-syndromic tooth agenesis family [J]. Journal of Shandong University (Health Sciences), 2019, 57(4): 97-100.
[10] DOU Chunhui, SHAO Jianhua, DONG Xuebin, ZHANG Ling, CHEN Ping, ZHAO Hongyu, GU Linping, SUN Lin, XIE Jie, WANG Min, WANG Juan, LI Na, LI Fan, LI Daqi. Effect of gene mutation on the clinical efficacy of decitabine for patients with myelodysplastic syndrome [J]. Journal of Shandong University (Health Sciences), 2019, 57(3): 42-48.
[11] ZHANG Wenhui, CHEN Yun, CHANG Yali, ZHOU Yawei, FANG Yunhai, ZHANG Xinsheng, GUO Nongjian. Gene detection and analysis of 55 patients with hemophilia A in Shandong Province [J]. Journal of Shandong University (Health Sciences), 2019, 57(12): 57-61.
[12] HU Liping, WANG Le, JIN Liang, LIU Yanxia, CUI Dongqing, CAO Lili. A case report and literature review of complex heterozygous SYNE1 mutation with autosomal recessive cerebellar ataxia type1 [J]. Journal of Shandong University (Health Sciences), 2019, 57(11): 78-82.
[13] XIAO Hongmei. Advance in genetic study on oocyte maturation failure [J]. Journal of Shandong University (Health Sciences), 2018, 56(4): 18-22.
[14] LIU Lianke, SHAO Mingwen, MA Lan, SUN Jing, GUAN Dan, SHU Yongqian. Clinico-pathological characteristics and diagnostic biomarkers in patients with esophageal carcinoma accompanied by neuroendocrine cell differentiation [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 87-91.
[15] LU Min, CHEN Yun, DING Botong, CHANG Yali, ZHOU Yawei, ZHAO Aiping, GUO Nongjian. Gene detection and analysis for hemophilia B among populations in Shandong Province [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(3): 87-92.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] SHI Shuang, LI Juan, MI Qi, WANG Yunshan, DU Lutao, WANG Chuanxin. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 47 -52 .
[2] HUANG Fei,WANG Huaijing,XING Yi,GAO Wei,LI Yonggang,XING Ziying,LI Zhenzhong. Protective effects of NGF and GM1 on primary sensory neurons in SD rat with sciatic nerve injury[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(4): 332 -335 .
[3] LI Wei,LI Dao-wei,YE Qian,GAO Shun-cui,JIANG Shu-juan.

Diagnostic value of transbronchial needle aspiration in paratracheal mediastinal lesions

[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(11): 1063 -1065 .
[4] TANG Fang1,2, ZHANG Yingqian3, WANG Zhiqiang4, KANG Dianmin4,
WANG Jiezhen1, XUE Fuzhong1. A 2D minimal spanning tree model of the spatial structures of natural focal disease[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(01): 106 -110 .
[5] JIANG Bao-dong,MA Xiang-xing,WANG Qing,WANG Qian,FENG Xiao-yuan,LI Ke,YU Fu-hua. Imaging parameters of multislice spiral CT venography in cerebral veins[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(11): 1084 -1086 .
[6] WANG Xu-ping,ZHAO Ling,FENG Yu-xin,SHANG Lin-shan,LIU Jin-cheng,. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(6): 564 -567 .
[7] WANG Xue-ping,YANG Hong-ling. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, (2): 213 .
[8] ZHU Xiaoli1, GUO Shuling1, SU Lei1, FENG Yuxin2, YUAN Fangshu1. Extraction of total proteins from demodex and qualification of their molecular weights[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(5): 58 -62 .
[9] ZHONG Nv-juan1, SONG Yong-mei2, LIU Gengsheng2, XUE Fu-zhong1, LIU Yan-xun1. Construction and application of the Bayes network model in
traditional Chinese medicine elements[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(2): 157 .
[10] LYU Longfei, LI Lin, LI Shuhai, QI Lei, LU Ming, CHENG Chuanle, TIAN Hui. Application of laparoscopic fine needle catheter jejunostomy in minimally invasive McKeown resection of esophageal cancer[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 77 -81 .
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd